NCT00355095View on ClinicalTrials.gov

Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

February 28, 2011

Study Completion Date

July 31, 2011

Conditions
Optic Neuritis
Interventions
DRUG

Erythropoietin

intravenous daily 3.3 \*10\^4 Units, duration 3 days

Trial Locations (3)

20246

University Hospital of Hamburg-Eppendorf (Institut of Neuroimmunology and Clinical MS Research (INIMS)), Hamburg

37075

Department of Neurology University Hospital Goettingen, Göttingen

66421

Department of Neurology University Homborg Hospital of the Saarland, Germany, Homburg

All Listed Sponsors
lead

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

OTHER

NCT00355095 - Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis | Biotech Hunter | Biotech Hunter